Syrjänen, Stina
Waterboer, Tim
Rintala, Marjut
Pawlita, Michael
Syrjänen, Kari
Louvanto, Karolina
Grenman, Seija
Funding for this research was provided by:
Päivikki and Sakari Sohlberg Foundation
Academy of Finland
the Finnish Cancer Foundation
the Turku University Foundation
Peter and Traudl Engelhorn-Stiftung
the Government Special Foundation for the Turku University Hospital
the Cancer Foundations of South-Western Finland
the Finnish Cultural Foundation
Article History
Received: 13 October 2021
Accepted: 21 January 2022
First Online: 9 February 2022
Competing interests
: Tim Waterboer serves on advisory boards for Merck (MSD) Sharp & Dohme. The other authors declare that they have no competing interests to disclose.